Wall Street analyst estimates for AN2 Therapeutics, Inc. (ANTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.20 | ||
| 2026-08-11 | $-0.18 | $-0.24 | +25.0% |
| 2026-05-11 | $-0.29 | $-0.23 | -26.1% |
| 2026-03-17 | $-0.29 | $-0.24 | -20.8% |
| 2025-11-12 | $-0.31 | $-0.23 | -34.8% |
| 2025-08-12 | $-0.21 | $-0.31 | +32.3% |
| 2025-05-13 | $-0.35 | $-0.26 | -34.6% |
| 2025-03-25 | $-0.25 | $-0.25 | +0.0% |
Valuation Ratios
| Price / Book | 3.15 |
| EV / EBITDA | -3.96 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $77000 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | -$77000 | 0 | 0 | 0 |
| Research & Development | $29.3M | $6.0M | $16.9M | $29.5M | $54.9M | $40.5M | $24.8M |
| Selling, General & Admin | $1.7M | $1.3M | $4.7M | $12.8M | $14.8M | $14.1M | $13.3M |
| Operating Expenses | $31.1M | $7.3M | $21.6M | $42.2M | $69.6M | $54.6M | $38.1M |
| Operating Income | -$31.1M | -$7.3M | -$21.6M | -$42.3M | -$69.6M | -$54.6M | -$38.1M |
| EBITDA | 0 | -$6.3M | -$21.5M | -$40.9M | $4.9M | $3.2M | -$35.2M |
| Interest Expense | 0 | 0 | 0 | $514000 | 0 | 0 | 0 |
| Pre-tax Income | -$33.8M | -$13.6M | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$33.8M | -$13.6M | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| EPS | $-0.30 | $-0.78 | $-1.50 | $-2.79 | $-2.74 | $-1.72 | $-1.16 |
| EPS (Diluted) | $-0.30 | $-0.78 | $-1.50 | $-2.79 | $-2.74 | $-1.72 | $-1.16 |
| Shares Outstanding (Diluted) | $18.7M | $18.7M | $18.7M | $15.3M | $23.6M | $29.8M | $30.2M |
Price
| Price | $5.34 |
| Market Cap | $192M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BOLD · IBIO · INTS · ITRM · NXTC · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of ANTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks